AUTL autolus.com: Enterprise Value to EBITDA Ratio

autolus.com (AUTL) - corporate logo

This chart's market price helps assess the potential of Autolus Therapeutics (AUTL), a British developer of CAR-T lymphoma treatments focused on the B2B sector. The business is currently scaling its first approved drug and developing a network of clinics with integrated logistics. FDA requirements and the need for specialized laboratories create a high barrier to entry, while the current EV/EBITDA ratio stands at 0.00, confirming the company's investment attractiveness.

Autolus Therapeutics PLC - AUTL Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/11/2026)

autolus.com (AUTL) - metric breakdowns and financial figures

- stock price and consensus target price:
Stock Quotes Autolus Pharma|AUTL - Average Forecast Price
- company stock capitalization data:
Market Valuation Autolus Corp|AUTL - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Autolus Therapeutics|AUTL - Company Net Assets|Market Capitalization to Book Value Ratio autolus.com|AUTL - Company Assets
- debt and solvency information:
Debt to Equity Autolus Therapeutics|AUTL - Long-Term Debt to Equity|Short-Term Debt to Equity Autolus Therapeutics plc|AUTL - Company Debts|Debt to Book Value Autolus Corp|AUTL - Company Long-Term Loans and Borrowings|Company Short-Term Debts Autolus Therapeutics|Quick Ratio autolus.com
- financial results and valuation multiples details:
AUTL - Company Net Income|Expected Profit Autolus Therapeutics|AUTL - Price to Earnings Multiple|Forward P/E Multiple Autolus Therapeutics|AUTL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Autolus Corp|AUTL - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Autolus Therapeutics|AUTL - Earnings per share for the last four quarters|Quarterly EPS earnings growth autolus.com|AUTL - Earnings per share increase in current year|Earnings growth forecast for next year Autolus Therapeutics
Summary company analytics:Autolus Pharma (AUTL)
Original product of Autolus Therapeutics plc

Autolus Therapeutics (AUTL) is actively developing the commercial potential of innovative CAR-T programs to combat hematological oncological diseases. The scaling of these technologies directly impacts the company's cost structure and operational efficiency. This ratio compares the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization to determine fundamental value. The current EV/EBITDA multiple valuation helps investors differentiate the growth phase from market overvaluation.

Key competitors

Legend Biotech Inc. - Enterprise Value to EBITDA Ratio|Sana Corp (SANA) - Company Value to EBITDA|ALLO: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RNAC (selectabio.com)|CLLS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Caribou Biosciences Inc.|TIL (Instil Bio, Inc) - EV/EBITDA Multiple|Company Value to EBITDA Genenta GNTA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Century Therapeutics (IPSC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization JSPR (jaspertherapeutics.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Senti Biosciences SNTI|Adaptimmune Therapeutics plc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CERO: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TCRT (Alaunos Therapeutics)|ACHL: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple cargo-tx.com CRGX|PSTX (Poseida Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA 2seventy bio Inc. TSVT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gracell Biotechnologies Ltd (GRCL)